It was a head-turning headline. Here's why the market was buzzing.

A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising ...

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in ...

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on ...

Moderna stock is a "Hold" due to persistent unprofitability, negative free cash flow, and a valuation highly dependent on ...

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a ...

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Billionaire biotech mogul Noubar Afeyan has called for urgent regulation of artificial intelligence agents that tech firms ...